Darunavir/r vs. Tipranavir/r in Treatment Experienced

POTENT Trial
Tipranavir/r versus Darunavir/r in Treatment-Experienced POTENT: Study Design

**Study Design: POTENT**

- **Background**: Randomized, open-label trial to compare the efficacy and safety of ritonavir-boosted tipranavir with ritonavir-boosted darunavir in triple-class treatment-experienced HIV-infected patients with PI resistance.

- **Inclusion Criteria (n=39)**
  - Triple class ARV treatment experience
  - HIV RNA ≥500 copies/mL
  - CD4 ≥50 cells/mm³
  - Documented resistance to more than one PI

- **Treatment Arms**
  - Tipranavir 500 mg BID + RTV 200 mg BID + OBR*
  - Darunavir 600 mg BID + RTV 100 mg bid + OBR*

*OBR = Optimized background regimen: ≥2 active antiretroviral agents

^Trial stopped early due to slow enrollment (only 39/800 randomized)

Tipranavir/r versus Darunavir/r in Treatment-Experienced POTENT: Result

Week 24: Virologic Data

Tipranavir/r versus Darunavir/r in Treatment-Experienced POTENT: Result

Week 32: Drug-Related Adverse Events

Conclusions/Significance: “TPV/r- and DRV/r-based regimens showed similar short-term safety and efficacy. These data support the use of next-generation PIs such as tipranavir or darunavir with novel class antiretroviral agents (integrase inhibitors, CCR5 antagonists, or fusion inhibitors).”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*